MarketPeel
Insider Trading Intelligence
JD

Jakob Dupont

ATRA
EVP, HEAD OF R&D · ATARA BIOTHERAPEUTICS, INC. · CIK 0001553335
FILING MIX · LIFETIME57%/43%
BUYS
31
SELLS
23
TOTAL VALUE
$963.9K
COMPANIES
4
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
699,755
AVG SELL PX
$8.08
TRADE KIND
SHOWING 54 / 54
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jakob Dupont, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+69.23%-6.26%-0.50%-5.76%-8.66%
14d13+76.92%-5.61%-0.29%-5.33%-7.25%
30d13+76.92%-9.83%-1.49%-8.34%-11.49%
60d13+92.31%-19.57%-1.62%-17.96%-16.11%
90d13+69.23%-20.16%-0.41%-19.76%-11.90%
180d13+84.62%-40.69%-2.46%-38.23%-54.87%
1y13+100.00%-73.02%-0.79%-72.23%-63.91%
2y13+100.00%-92.25%+20.72%-112.97%-109.62%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ATRA · 290,794 shares · as of Mar 2, 2023
079,497158,994238,490317,987202120222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 31 buys / 23 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PYXS
PYXIS ONCOLOGY, INC.
SALE
35,000357,461Jun 30, 2026Jul 2, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
35,000$3.06$107.1K38,741Jun 30, 2026Jul 2, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
35,000$1.60$56.0K73,741Jun 30, 2026Jul 2, 2026View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jun 10, 2026Jun 11, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
45,86745,867Mar 24, 2026Mar 25, 2026View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
849849Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
8490Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,0001,000Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
1,0000Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
1,1000Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
2,5000Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,5002,500Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,1001,100Dec 12, 2025Dec 16, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,1001,100May 27, 2025Jul 2, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,00020,000May 1, 2025May 1, 2025View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
36,979$0.98$36.2K36,979Mar 31, 2025Apr 2, 2025View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,98416,984Sep 3, 2024Sep 6, 2024View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000Sep 3, 2024Sep 6, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
38,74138,741Mar 26, 2024Mar 28, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
392,461392,461Sep 22, 2023Sep 26, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
3,5343,534Aug 23, 2023Aug 25, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
5,8795,879Aug 23, 2023Aug 25, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
17,25017,250Aug 23, 2023Aug 25, 2023View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,074$3.63$18.4K290,794Mar 2, 2023Mar 6, 2023View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
141,328295,868Mar 1, 2023Mar 3, 2023View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
317,987317,987Mar 1, 2023Mar 3, 2023View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
3,218$4.49$14.4K155,664Nov 16, 2022Nov 18, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
1,124$4.49$5.0K154,540Nov 16, 2022Nov 18, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
4,124$5.03$20.8K158,882Aug 16, 2022Aug 18, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
3,873$5.32$20.6K163,006May 17, 2022May 19, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
78,506169,100Mar 1, 2022Mar 3, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
147,573147,573Mar 1, 2022Mar 3, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
2,221$9.86$21.9K166,879Mar 1, 2022Mar 3, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000$16.00$80.0K90,594Feb 10, 2022Feb 14, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASE
EVP, Head of R&D
5,000$9.58$47.9K95,594Feb 10, 2022Feb 14, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000257,500Feb 10, 2022Feb 14, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000$16.01$80.0K90,594Jan 3, 2022Jan 5, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000262,500Jan 3, 2022Jan 5, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASE
EVP, Head of R&D
5,000$9.58$47.9K95,594Jan 3, 2022Jan 5, 2022View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000$17.94$89.7K90,594Dec 1, 2021Dec 3, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASE
EVP, Head of R&D
5,000$9.58$47.9K95,594Dec 1, 2021Dec 3, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000267,500Dec 1, 2021Dec 3, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
2,199$17.12$37.6K90,594Nov 16, 2021Nov 18, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000$16.41$82.0K92,793Nov 2, 2021Nov 4, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,000272,500Nov 2, 2021Nov 4, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASE
EVP, Head of R&D
5,000$9.58$47.9K97,793Nov 2, 2021Nov 4, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
2,152$12.53$27.0K92,793Aug 17, 2021Aug 19, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
SALE
EVP, Head of R&D
5,184$14.55$75.4K94,945May 18, 2021May 20, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,879100,129Mar 1, 2021Mar 3, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
81,32781,327Mar 1, 2021Mar 3, 2021View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
46,25046,250May 14, 2020May 19, 2020View →
ATRA
ATARA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
277,500277,500May 14, 2020May 19, 2020View →
GOSS
GOSSAMER BIO, INC.
PURCHASEGRANT
Stock grant
71,50071,500Feb 14, 2020Feb 19, 2020View →
GOSS
GOSSAMER BIO, INC.
PURCHASEGRANT
Stock grant
46,50046,500Feb 14, 2020Feb 19, 2020View →
Other insiders · ATRA
Loading peer insiders…
About this filer
CIK 0001553335
ROLE
EVP, Head of R&D
PRIMARY
ATRA
COMPANIES
4
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001553335DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback